search
Back to results

Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

Primary Purpose

Fractures, Open, Surgical Wound Infection

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Vancomycin
Sponsored by
University of Tennessee
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Fractures, Open focused on measuring Vancomycin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Skeletally mature patients ≥18 years of age
  • Acute Gustilo-Anderson Type I-IIIA open fracture
  • Fracture is deemed primarily closable at initial surgery
  • Likely to follow-up with surgeon until fracture is healed
  • Ability to understand and agree to Informed Consent

Exclusion Criteria:

  • Patients <18 years of age
  • Gustilo-Anderson Type IIIB and IIIC open fractures
  • Open fractures requiring multiple operations (i.e. for repeat surgical debridement or staged bone grafting of critical segmental defects)
  • Delayed presentation of open fracture
  • Pre-existing systemic infection requiring antibiotic therapy
  • Allergy to Vancomycin
  • Open fracture at the site of a previous fracture or surgical site
  • Current skin infection, chronic wounds or known systemic infection
  • Unlikely to follow-up until fracture is healed
  • Unable to understand or agree to Informed Consent

Sites / Locations

  • Erlanger Health System

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Vancomycin Powder

Standard Treatment

Arm Description

If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.

If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.

Outcomes

Primary Outcome Measures

Postoperative Infection
Infections will be considered clinically significant if they require a return to the operating suite for surgical debridement. These infections will be classified as acute infections and/or chronic osteomyelitis. Superficial skin infections will be treated with local wound care, oral antibiotics and incision and drainage (as indicated). Deep infections and chronic osteomyelitis will be treated with staged serial surgical debridement, hardware removal (as indicated), culture specific IV antibiotics, and Infectious Disease consultation.

Secondary Outcome Measures

Full Information

First Posted
March 23, 2015
Last Updated
November 27, 2018
Sponsor
University of Tennessee
search

1. Study Identification

Unique Protocol Identification Number
NCT02400112
Brief Title
Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures
Official Title
Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Terminated
Why Stopped
Low enrollment; Low clinical relevance: evidence for use of vancomycin powder
Study Start Date
March 2015 (undefined)
Primary Completion Date
October 2018 (Actual)
Study Completion Date
October 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Tennessee

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if local administration of vancomycin powder at the site of Grade I-IIIA open fractures at the time of surgery will be an efficacious method to lower infection rates in open fracture treatment and to elucidate any detrimental effects of applying vancomycin powder at the site of open fractures.
Detailed Description
Hypothesis: Local administration of 1 gram of vancomycin powder at the site of primarily closeable Gustilo-Anderson Grade I-IIIA open fractures at the time of surgery, in addition to clinically accepted open fracture management (intravenous antibiotics, surgical irrigation and debridement and stabilization), will significantly decrease the postoperative infection rate in comparison to the current treatment algorithm. Methods: Study subjects will be randomized to one of two groups prior to surgery (parallel group design): standard treatment (control group) versus vancomycin powder treatment (experimental group). Each group will have an equal number of subjects. Once randomized, the intervention is then un-blinded to facilitate treatment. Post-operatively, all patients will receive intravenous antibiotics, such that all patients receive a total of 24 hours of intravenous antibiotics. The surgical drain will be removed at the patient's bedside approximately 24 hours after the surgical procedure. Patients will follow up with their surgeon for routine scheduled visits at approximately 2 weeks, 6 weeks, 12 weeks, and further until aseptic union or resolution of infection. There will be no additional appointments solely for the purpose of research follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fractures, Open, Surgical Wound Infection
Keywords
Vancomycin

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vancomycin Powder
Arm Type
Experimental
Arm Description
If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
Arm Title
Standard Treatment
Arm Type
No Intervention
Arm Description
If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Intervention Description
Vancomycin powder administered locally, intraoperatively at site of open fracture
Primary Outcome Measure Information:
Title
Postoperative Infection
Description
Infections will be considered clinically significant if they require a return to the operating suite for surgical debridement. These infections will be classified as acute infections and/or chronic osteomyelitis. Superficial skin infections will be treated with local wound care, oral antibiotics and incision and drainage (as indicated). Deep infections and chronic osteomyelitis will be treated with staged serial surgical debridement, hardware removal (as indicated), culture specific IV antibiotics, and Infectious Disease consultation.
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Skeletally mature patients ≥18 years of age Acute Gustilo-Anderson Type I-IIIA open fracture Fracture is deemed primarily closable at initial surgery Likely to follow-up with surgeon until fracture is healed Ability to understand and agree to Informed Consent Exclusion Criteria: Patients <18 years of age Gustilo-Anderson Type IIIB and IIIC open fractures Open fractures requiring multiple operations (i.e. for repeat surgical debridement or staged bone grafting of critical segmental defects) Delayed presentation of open fracture Pre-existing systemic infection requiring antibiotic therapy Allergy to Vancomycin Open fracture at the site of a previous fracture or surgical site Current skin infection, chronic wounds or known systemic infection Unlikely to follow-up until fracture is healed Unable to understand or agree to Informed Consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dirk W Kiner, MD
Organizational Affiliation
University of Tennessee College of Medicine Chattanooga/Erlanger Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Erlanger Health System
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

We'll reach out to this number within 24 hrs